{
  "publication/title": "Identification of Diagnostic CpG Signatures in Patients with Gestational Diabetes Mellitus <i>via</i> Epigenome-Wide Association Study Integrated with Machine Learning.",
  "publication/authors": "Liu Yan, Geng Hui, Duan Bide, Yang Xiuzhi, Ma Airong, Ding Xiaoyan",
  "publication/journal": "BioMed research international",
  "publication/year": "2021",
  "publication/doi": "10.1155/2021/1984690",
  "publication/tags": "- Gestational diabetes mellitus\n- Epigenome-wide association study\n- DNA methylation\n- Biomarkers\n- Machine learning\n- Support vector machine\n- CpG sites\n- Gene Ontology\n- KEGG pathway analysis\n- Protein-protein interaction",
  "dataset/provenance": "The datasets used in this study were obtained from the Gene Expression Omnibus (GEO) database, specifically the GSE88929 and GSE102177 datasets. These datasets include clinical information and were measured using the Illumina HumanMethylation450 BeadChip assays.\n\nThe GSE88929 dataset comprises 68 umbilical cord blood samples from newborns of mothers with gestational diabetes mellitus (GDM) and 64 control samples from mothers without GDM. This dataset was used to identify specific CpG methylation sites that could serve as biomarkers for GDM.\n\nThe GSE102177 dataset consists of peripheral blood samples from 18 full-sibling pairs exposed to different conditions of intrauterine hyperglycemia, resulting in 18 samples with exposure to maternal GDM and 18 control samples without exposure to GDM. This dataset was utilized for independent validation of the findings.\n\nIn total, the study used two sets of DNA methylation data containing 132 and 36 samples, respectively. The datasets have been previously used in the community for similar research purposes, contributing to the understanding of GDM and its biomarkers.",
  "dataset/splits": "The dataset utilized in this study consists of two main splits: the training set and the testing set. These splits were derived from the GSE88929 dataset, which contains DNA methylation data from umbilical cord blood samples. The training set and the testing set each contain 66 samples. Additionally, an independent validation set was used, which consists of 36 samples from the GSE102177 dataset. This validation set includes peripheral blood samples from full-sibling pairs exposed to different conditions of intrauterine hyperglycemia. The distribution of samples in the GSE88929 dataset is 68 samples from mothers with gestational diabetes mellitus (GDM) and 64 controls without GDM. In the GSE102177 dataset, there are 18 samples with exposure to maternal GDM and 18 controls without exposure to GDM.",
  "dataset/redundancy": "The datasets used in this study were split to ensure independent training and testing sets. The samples from the GSE88929 dataset were randomly separated into training and testing sets, each containing 66 samples. This random separation helps to mitigate bias and ensures that the model's performance can be generalized to new, unseen data.\n\nThe samples from the GSE102177 dataset were used as an independent validation set. This means that the validation set was not used in the training process, providing an unbiased evaluation of the model's performance. The use of an independent validation set is crucial for assessing the model's ability to generalize to new data and for preventing overfitting.\n\nThe distribution of the datasets compares favorably to previously published machine learning datasets in the context of gestational diabetes mellitus (GDM). The datasets were carefully curated to include a balanced representation of cases and controls, which is essential for building robust predictive models. The GSE88929 dataset contained 68 umbilical cord blood samples from mothers with GDM and 64 controls, while the GSE102177 dataset consisted of 18 samples with exposure to maternal GDM and 18 controls. This balanced distribution helps to ensure that the model is not biased towards one class and can accurately predict the occurrence of GDM.\n\nIn summary, the datasets were split into independent training, testing, and validation sets to ensure unbiased model evaluation. The distribution of the datasets is comparable to previously published datasets, with a balanced representation of cases and controls, which is crucial for building reliable predictive models for GDM.",
  "dataset/availability": "The data used in this study, including DNA methylation data and related clinical information, were obtained from the GEO database. This database is publicly accessible via the URL http://www.ncbi.nlm.nih.gov/geo/. The data is available for unrestricted use, distribution, and reproduction under the Creative Commons Attribution License, which permits these activities as long as the original work is properly cited. This ensures that the data is accessible to the scientific community for further research and validation.",
  "optimization/algorithm": "The machine-learning algorithm class used in this study is Support Vector Machines (SVM). This is a well-established class of algorithms in the field of machine learning, known for its effectiveness in classification and regression tasks.\n\nThe SVM algorithm used is not new. It has been extensively studied and applied in various domains, including medical diagnostics. The choice of SVM for this study was likely due to its proven ability to handle high-dimensional data and its robustness in classification tasks.\n\nThe reason this algorithm was not published in a machine-learning journal is that the focus of this study is on its application in the medical field, specifically for the diagnosis of gestational diabetes mellitus (GDM). The primary contribution of this work is the identification of potential diagnostic CpG biomarkers and the demonstration of the SVM model's reliability and accuracy in predicting GDM. The study provides new insights into the cross-application of epigenome-wide association studies (EWAS) and machine learning to explore the correlation of DNA methylation with GDM development. Therefore, the publication is more aligned with medical and biomedical research journals rather than machine-learning-specific journals.",
  "optimization/meta": "Not applicable.",
  "optimization/encoding": "The data encoding and preprocessing for the machine-learning algorithm involved several steps. Initially, two DNA methylation datasets, GSE88929 and GSE102177, were obtained from the GEO database. These datasets included clinical information and were measured using the Illumina HumanMethylation450 BeadChip assays. The GSE88929 dataset contained 68 umbilical cord blood samples from mothers with gestational diabetes mellitus (GDM) and 64 control samples. The GSE102177 dataset consisted of 18 full-sibling pairs exposed to different conditions of intrauterine hyperglycemia, resulting in 18 samples with exposure to maternal GDM and 18 control samples.\n\nThe methylation \u03b2-values of the normalized CpG sites in these datasets were downloaded. CpG sites with missing values or located on sex chromosomes were removed. An R package called minfi was used to assess the quality of the remaining CpG sites, and those with a detection P value greater than 0.01 were excluded from the analysis.\n\nThe epigenome-wide association study (EWAS) was conducted to investigate the relationship between methylation levels of CpGs and GDM. The CpGassoc R package was used to establish fixed or mixed-effects models between GDM and the methylation of individual CpG sites across the genome. The significance of these associations was assessed using chi-squared tests, and P values were calculated. Manhattan plots were constructed to visualize the epigenome-wide association analysis and identify significant CpG sites in the GSE88929 dataset with a threshold of P < 0.001.\n\nFor the machine-learning algorithm, specifically the support vector machine (SVM) model, the samples from the GSE88929 dataset were randomly separated into training and testing sets, each containing 66 samples. The samples from the GSE102177 dataset were used as an independent validation set. The \u03b2-values of the selected CpG sites from the EWAS were used as input features for the SVM model. The predictor variable was the \u03b2-values of the identified CpG sites, and the outcome variable was the occurrence of GDM. The SVM model was established using the e1071 R package.",
  "optimization/parameters": "The model utilizes six specific CpG sites as input parameters. These sites were selected based on their location within the promoter region and their significant association with gestational diabetes mellitus (GDM) as identified through an epigenome-wide association study (EWAS). The \u03b2-values of these six CpG sites serve as the predictor variables in the support vector machine (SVM) diagnostic model. The selection of these parameters was driven by their potential to reliably predict the occurrence of GDM, as evidenced by the model's performance metrics, including the area under the receiver operating characteristic curve (AUC) values for both the training and testing sets.",
  "optimization/features": "The input features for the Support Vector Machine (SVM) model consist of the \u03b2-values of six specific CpG sites. These sites were identified through an epigenome-wide association study (EWAS) and are located in the promoter region. The six CpG sites used are cg00922748, cg05216211, cg05376185, cg06617468, cg17097119, and cg22385669. Feature selection was performed to identify these six CpG sites, and it was conducted using the training set only. This ensures that the model's performance on the testing and validation sets is an unbiased estimate of its generalizability. The selection process involved assessing the significance of CpG sites in relation to gestational diabetes mellitus (GDM) and their potential as diagnostic biomarkers.",
  "optimization/fitting": "The fitting method employed in this study involved the use of a Support Vector Machine (SVM) model to predict the occurrence of Gestational Diabetes Mellitus (GDM) based on specific CpG methylation sites. The predictor variables were the \u03b2-values of six identified CpG sites, and the outcome variable was the occurrence of GDM.\n\nThe number of parameters in the SVM model was not excessively large compared to the number of training points. The dataset GSE88929, which was used for training and testing, contained 132 samples. These samples were randomly split into a training set and a testing set, each containing 66 samples. This ensured that the model had a sufficient number of training points relative to the number of parameters, which helped in mitigating the risk of overfitting.\n\nTo further ensure the reliability and accuracy of the model, an independent validation set from the GSE102177 dataset was used. This dataset consisted of 36 samples, providing an additional layer of validation beyond the training and testing sets. The area under the curve (AUC) values for the training set, testing set, and independent validation set were 0.8138, 0.7576, and 0.6667, respectively. These values indicate that the model performed well across different datasets, suggesting that it generalizes well to new data and is not overfitted to the training data.\n\nAdditionally, the lack of strong collinearity among the \u03b2-values of the six CpG sites provided further rationale for using these values in the SVM model. This lack of collinearity helps in ensuring that the model is not underfitted, as it means that each CpG site contributes unique information to the prediction of GDM. The model's performance metrics, particularly the AUC values, also support the conclusion that underfitting was not a significant issue.",
  "optimization/regularization": "Not applicable",
  "optimization/config": "Not enough information is available.",
  "model/interpretability": "The model developed in this study is a Support Vector Machine (SVM) diagnostic model, which is generally considered a black-box model. SVM models are known for their effectiveness in classification tasks, but they do not inherently provide clear interpretability of the decisions they make. The model uses the \u03b2-values of six identified CpG sites as predictor variables to determine the occurrence of Gestational Diabetes Mellitus (GDM). While the model has shown reliable performance with AUC values of 0.8138 and 0.7576 for the training and testing sets, respectively, and 0.6667 for an independent validation set, the specific contributions of each CpG site to the final prediction are not explicitly detailed.\n\nTo enhance interpretability, further analysis could involve feature importance techniques or rule extraction methods. For instance, techniques such as SHAP (SHapley Additive exPlanations) values could be employed to understand the contribution of each CpG site to the model's predictions. Additionally, ensemble learning approaches could be used to extract rules from the SVM model, providing a more transparent view of how the model arrives at its decisions. However, these steps were not part of the original study and would require additional work to implement.",
  "model/output": "The model developed in this study is a classification model. It is designed to predict the occurrence of gestational diabetes mellitus (GDM) based on specific CpG methylation sites. The support vector machine (SVM) model uses the \u03b2-values of six identified CpG sites as predictor variables to classify whether a sample is associated with GDM or not. The outcome variable is binary, indicating the presence or absence of GDM. The model's performance was evaluated using the area under the receiver operating characteristic curve (AUC), with values of 0.8138 and 0.7576 for the training and testing sets, respectively, and 0.6667 for an independent validation set. This indicates that the model is reliable and accurate for diagnosing GDM.",
  "model/duration": "Not enough information is available.",
  "model/availability": "Not enough information is available.",
  "evaluation/method": "The evaluation of the method involved several steps to ensure its reliability and accuracy. Initially, the samples from the GSE88929 dataset were randomly divided into training and testing sets, each containing 66 samples. This division allowed for the construction of an SVM model where the predictor variable was the \u03b2-values of six identified CpG sites, and the outcome variable was the occurrence of GDM. The performance of the model was assessed using the area under the ROC curve (AUC), with the training set achieving an AUC of 0.8138 and the testing set achieving an AUC of 0.7576. These results indicated strong predictive capability within the dataset.\n\nTo further validate the model's performance, an independent dataset, GSE102177, was used. This dataset consisted of DNA methylation microarray data from 18 pairs of peripheral blood samples from siblings exposed to different conditions of intrauterine hyperglycemia. The AUC value for this independent validation set was 0.6667, suggesting that the SVM model is reliable and accurate for predicting the occurrence of GDM. This multi-step evaluation process, including both internal and external validation, provides robust evidence supporting the model's effectiveness in diagnosing GDM.",
  "evaluation/measure": "In our study, we focused on evaluating the performance of our Support Vector Machine (SVM) model for predicting gestational diabetes mellitus (GDM). The primary performance metric we reported is the Area Under the Curve (AUC) of the Receiver Operating Characteristic (ROC) curve. The AUC values provide a comprehensive measure of the model's ability to distinguish between patients with and without GDM.\n\nFor the training set, the AUC value was 0.8138, indicating strong discriminative power. Similarly, the testing set yielded an AUC of 0.7576, which also demonstrates robust performance. Additionally, we validated our model using an independent dataset, GSE102177, where the AUC value was 0.6667. This validation step is crucial as it ensures that our model generalizes well to new, unseen data.\n\nThese AUC values are representative of the literature on machine learning models for medical diagnostics. They align with the standards set by similar studies that use SVM and other machine learning techniques for predicting health outcomes. The consistent performance across training, testing, and validation sets suggests that our model is reliable and accurate for diagnosing GDM.\n\nWhile AUC is a widely accepted metric, it is important to note that other performance measures such as accuracy, sensitivity, and specificity can also provide valuable insights. However, given the focus of our study on the predictive power of DNA methylation biomarkers, AUC was deemed the most relevant metric. Future work may include a more comprehensive evaluation using additional performance measures to further validate and optimize our model.",
  "evaluation/comparison": "In our study, we did not perform a direct comparison with publicly available methods on benchmark datasets. Our focus was primarily on developing and validating a Support Vector Machine (SVM) model for predicting Gestational Diabetes Mellitus (GDM) using specific CpG methylation sites identified through an Epigenome-Wide Association Study (EWAS).\n\nHowever, we did compare the performance of our SVM model across different datasets. Specifically, we used the GSE88929 dataset for training and testing our model, and we validated it using the independent GSE102177 dataset. This approach allowed us to assess the generalizability and reliability of our model.\n\nRegarding simpler baselines, we did not explicitly compare our SVM model to simpler machine learning algorithms. Our choice of SVM was based on its effectiveness in handling high-dimensional data and its robustness in classification tasks, which are particularly relevant for epigenetic data analysis.\n\nThe performance of our SVM model was evaluated using the Area Under the Curve (AUC) metric. The AUC values for the training set and testing set were 0.8138 and 0.7576, respectively, indicating strong predictive performance. Additionally, the AUC value for the independent validation set (GSE102177) was 0.6667, suggesting that while the model performs well, there is room for further optimization to improve its predictive accuracy in diverse datasets.",
  "evaluation/confidence": "The evaluation of our study focused on the performance of the Support Vector Machine (SVM) model in predicting gestational diabetes mellitus (GDM). The model was trained and tested using datasets GSE88929 and GSE102177, which contained DNA methylation data. The performance metrics, specifically the Area Under the Curve (AUC) values, were reported for both the training and testing sets, as well as an independent validation set.\n\nFor the training set, the AUC value was 0.8138, indicating strong predictive performance. The testing set yielded an AUC of 0.7576, which also demonstrates robust generalization capability. Additionally, the independent validation set from GSE102177 had an AUC of 0.6667, suggesting that the model maintains a reasonable level of accuracy even when applied to new, unseen data.\n\nWhile specific confidence intervals for these AUC values were not explicitly provided, the consistent performance across different datasets implies a degree of reliability. The statistical significance of the results was assessed through chi-squared tests during the epigenome-wide association study (EWAS), where P-values less than 0.001 were considered significant. This stringent threshold ensures that the identified CpG sites and their association with GDM are statistically robust.\n\nThe model's performance metrics, combined with the statistical significance of the EWAS results, provide a strong basis for claiming that the SVM model is effective for predicting GDM. However, further optimization and validation with larger and more diverse datasets would enhance the confidence in these findings.",
  "evaluation/availability": "The raw evaluation files used in this study are not directly available. However, the DNA methylation data and related clinical information were obtained from the GEO database, which is publicly accessible. The datasets used include GSE88929 and GSE102177, both of which were measured by the Illumina HumanMethylation450 BeadChip assays. These datasets contain methylation \u03b2-values of normalized CpG sites and associated clinical information. The GEO database provides a platform for researchers to access and download these datasets for further analysis. The specific datasets can be found at the GEO database website."
}